Ledyard National Bank Has $5.44 Million Holdings in Pfizer Inc. (NYSE:PFE)

Ledyard National Bank trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 17.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 205,123 shares of the biopharmaceutical company’s stock after selling 42,815 shares during the period. Ledyard National Bank’s holdings in Pfizer were worth $5,442,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Leo Wealth LLC grew its position in shares of Pfizer by 48.8% in the 4th quarter. Leo Wealth LLC now owns 35,767 shares of the biopharmaceutical company’s stock valued at $949,000 after acquiring an additional 11,722 shares during the period. Encompass Wealth Advisors LLC lifted its stake in Pfizer by 12.9% in the 4th quarter. Encompass Wealth Advisors LLC now owns 13,686 shares of the biopharmaceutical company’s stock valued at $363,000 after purchasing an additional 1,560 shares during the last quarter. Iron Horse Wealth Management LLC increased its position in Pfizer by 119.6% during the fourth quarter. Iron Horse Wealth Management LLC now owns 1,836 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 1,000 shares during the last quarter. Consolidated Portfolio Review Corp bought a new stake in Pfizer in the fourth quarter valued at approximately $3,192,000. Finally, Telos Capital Management Inc. lifted its position in shares of Pfizer by 8.1% in the fourth quarter. Telos Capital Management Inc. now owns 23,292 shares of the biopharmaceutical company’s stock valued at $618,000 after buying an additional 1,739 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

Pfizer stock opened at $25.83 on Friday. The firm has a market cap of $146.35 billion, a PE ratio of 34.90, a price-to-earnings-growth ratio of 0.66 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock’s fifty day moving average price is $26.29 and its two-hundred day moving average price is $27.78. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter last year, the business earned $0.10 earnings per share. Pfizer’s revenue was up 24.7% on a year-over-year basis. As a group, research analysts expect that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.66%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is 232.44%.

Analysts Set New Price Targets

PFE has been the topic of a number of recent analyst reports. Wolfe Research initiated coverage on Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 target price on the stock. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. UBS Group cut their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Sanford C. Bernstein assumed coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target on the stock. Finally, Citigroup reduced their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.